Please find enclosed herewith the Business Responsibility and Sustainability Report for the financial year 2025-26

August 1, 2026 BSE Limited National Stock Exchange of India Limited Floor 25, P. J. Towers Exchange Plaza, Bandra Kurla Complex, Dalal Street, Fort Bandra (E), Mumbai - 400 001 Mumbai - 400 051 Symbol: JUBLPHARMA Scrip Code: 530019 Sub.: Business Responsibility and Sustainability Report (‘BRSR’) for the Financial Year 2025-26 Ref.: Regulation 34(2)(f) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations) Dear Madam/Sirs, Pursuant to Regulation 34 of the Listing Regulations, please find enclosed the Business Responsibility and Sustainability Report ("BRSR") for FY 2025-26, which also forms part of the Annual Report for the Financial Year 2025-26. This is for your information and record. Thanking you, Yours faithfully, For Jubilant Pharmova Limited Naresh Kapoor Company Secretary Encl.: As above JUBILANT PHARMOVA LIMITED Annexure II Business Responsibility & Sustainability Report SECTION A: GENERAL DISCLOSURES I. Details of the listed entity 1. Corporate Identity Number (CIN) of the Listed Entity L24116UP1978PLC004624 2. Name of the Listed Entity Jubilant Pharmova Limited 3. Year of incorporation 1978 4. Registered office address Bhartiagram, Gajraula, District Amroha-244 223, Uttar Pradesh, India 5. Corporate address 1A, Sector 16A, Noida - 201 301, Uttar Pradesh 6. E-mail Naresh.Kapoor@jubl.com 7. Telephone 91-120-4361000 8. Website www.jubilantpharmova.com 9. Financial year for which reporting is being done FY25-26 10. Name of the Stock Exchange(s) where shares are listed: • National Stock Exchange of India Limited • BSE Limited 11. Paid-up Capital INR 159281139 12. Name and contact details (telephone, email address) of Naresh Kapoor [Sr. VP & Head – Secretarial (CS&VP)] the person who may be contacted in case of any queries Jubilant Pharmova Limited on the BRSR report: Plot 1A, Sector 16A, Noida, Uttar Pradesh - 201301 13. Reporting boundary - Are the disclosures under this Disclosures are made on a consolidated basis (Report report made on a standalone basis (i.e. only for the boundary covers Jubilant Pharmova Limited and its entity) or on a consolidated basis (i.e. for the entity subsidiaries which forms part of the consolidated basis and all the entities that form a part of its consolidated unless otherwise stated). For environmental & safety financial statements, taken together) performance all facilities and & R&Ds in operation are considered, excluding registered & corporate office. 14. Name of assurance provider TUV SUD SOUTH ASIA PVT. LTD. 15. Type of assurance obtained Reasonable Assurance – BRSR Core II. Products/services 16. Details of business activities (accounting for 90% of the turnover): S. Description of Main Activity Description of Business Activity % of Turnover No. of the entity 1 Radiopharma Radiopharma 44.57% 2 Allergy Immunotherapy Allergy Immunotherapy 9.48% 3 Contract Development and Manufacturing Contract Development and Manufacturing 21.19% Organisation - Sterile Injectables Organisation - Sterile Injectables 4 Generics Generics 9.34% 5 Contract Research, Development and Contract Research, Development and 14.70% Manufacturing Organisation Manufacturing Organisation 6 Proprietary Novel Drugs Proprietary Novel Drugs 0.00% 7 Management Services Management Services 0.71% ANNUAL REPORT 2025-26 01 JUBILANT PHARMOVA LIMITED 17. Products/Services sold by the entity (accounting for 90% of the entity’s Turnover): S. Product/Service NIC Code % of total Turnover No. contributed 1 Radiopharmaceuticals 21002 44.57 2 Contract manufacturing operations 21002 21.19 3 Allergy therapy products 21002 9.49 4 Solid dosage formulations 21002 8.66 5 Active pharmaceutical ingredients 21001 6.81 6 Contract Research and Development Services 72100 7.89 7 India branded pharmaceuticals 46497 0.68 8 Management Services 70200 0.71 9 Proprietary Noval Drugs 72100 0.0 III. Operations 18. Number of locations where plants and/or operations/offices of the entity are situated: Location Number of plants Number of offices Total National 2 2* 4 International 3 8 11 *includes registered office & corporate office 19. Markets served by the entity: a. Number of locations Locations Number National (No. of States) 21 International (No. of Countries) 74 b. What is the contribution of exports as a percentage of the total turnover of the entity? 63.53% (standalone continuing operation basis) c. A brief on types of customers: T he Company serves leading Pharmaceutical companies, Biotech companies, Group Purchasing Organisations (‘GPOs’), allergists and hospitals in various markets by offering API, Solid Dosage Form, Allergy Immunotherapy Products, Radio Pharmaceuticals Products, Contract Manufacturing of sterile and non-sterile injectables, Compounding and dispensing of Radiopharmaceuticals products, Contract Research and Development Services. Through India Branded Pharmaceuticals business, the Company sells branded pharmaceuticals in the India market. IV. Employees 20. Details at the end of the Financial Year: 2026 a. Employees and workers (including differently abled): S. Particulars Total Male Female (A) No. (B) % (B / A) No. (C) % (C / A) EMPLOYEES 1 Permanent (D) 3762 2799 74 963 26 2 Other than Permanent ( E) 24 11 46 13 54 3 Total employees (D + E) 3786 2810 74 976 26 WORKERS 4 Permanent (F) 1895 1450 77 445 23 5 Other than Permanent (G) 705 688 98 17 2 6 Total workers (F+G) 2600 2138 82 462 18 ANNUAL REPORT 2025-26 02 JUBILANT PHARMOVA LIMITED b. Differently abled Employees and workers: S. Particulars Total (A) Male Female No. (B) % (B / A) No. (C) % (C / A) DIFFERENTLY ABLED EMPLOYEES 1 Permanent (D) 32 20 63 12 38 2 Other than Permanent (E) 25 0 0 25 100 3 Total differently abled employees (D + E) 57 20 35 37 65 DIFFERENTLY ABLED WORKERS 4 Permanent (F) 1 1 100 0 0 5 Other than permanent (G) 0 0 0 0 0 6 Total differently-abled workers (F + G) 1 1 100 0 0 21. Participation/Inclusion/Representation of women Total No. and percentage of Females No. (B) % (B / A) Board of Directors 10 1 10 Key Management Personnel 4 0 0 22. Turnover rate for permanent employees and workers (Disclose trends for the past 3 years) FY26 (Turnover rate in FY25 (Turnover rate in FY24 (Turnover rate in current FY) current FY) previous FY) Male Female Total Male Female Total Male Female Total Permanent Employees 19% 16% 18% 23% 17% 22% 27% 25% 26% Permanent Workers 10% 11% 10% 10% 14% 11% 15% 15% 15% V. Holding, Subsidiary and Associate Companies (including joint ventures) 23. (a) Names of holding / subsidiary / associate companies / joint ventures M ost company level policies & practices essential for the Company are also extended to the subsidiaries and associates. Our subsidiaries and stepdown subsidiaries participate in the sustainability and business responsibility initiatives of the Company. S. Name of the holding / subsidiary Indicate whether % of Does the entity indicated No. / associate companies / joint holding/ shares at column A, participate in ventures (A) Subsidiary/ held by the Business Responsibility Associate/ Joint listed initiatives of the listed Venture entity entity? (Yes/No) 1 Jubilant Pharma Limited Subsidiary 100 Yes 2 Jubilant Generics Limited Subsidiary 100 Yes 3 Jubilant Cadista Pharmaceuticals Inc. Subsidiary 100 Yes 4 Jubilant HollisterStier LLC Subsidiary 100 Yes 5 Jubilant Pharma NV Subsidiary 100 Yes 6 Jubilant Pharmaceuticals NV Subsidiary 100 Yes 7 PSI Supply NV Subsidiary 100 Yes 8 Jubilant Therapeutics Inc. Subsidiary 98.54 Yes 9 Jubilant Pharma Holdings Inc. Subsidiary 100 Yes 10 Jubilant Biosys Limited Subsidiary 100 Yes 11 Jubilant Pharma Australia Pty. Limited Subsidiary 100 Yes 12 Jubilant Innovation (USA) Inc. Subsidiary 100 Yes 13 Jubilant HollisterStier Inc. Subsidiary 100 Yes ANNUAL REPORT 2025-26 03 JUBILANT PHARMOVA LIMITED S. Name of the holding / subsidiary Indicate whether % of Does the entity indicated No. / associate companies / joint holding/ shares at column A, participate in ventures ( [Showing first 8,000 characters — download PDF for full document]